ArticleMolecular therapy. Nucleic acids2025

A potent GalNAc-siRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection.

Shuquan Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.